Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

What Was Tested

Researchers studied Liraglutide in this randomized controlled trial publication.

To evaluate routinely collected data on nausea and vomiting among individuals on liraglutide and their influence on tolerability and body weight.

Why It Was Studied

Nausea was the most frequent side effect.

Who Took Part

The study group was 564 participants.

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and placebo-controlled study.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

Being open-label, the Liraglutide study did not mask who received what.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

A time span of 1 year appears in the methods.

What Was Measured

The subject headings attached to it are Anti-Obesity Agents, Body Mass Index, Europe, Glucagon-Like Peptide 1, Liraglutide, Nausea and Obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Liraglutide in 564 participants over 1 year.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (International journal of obesity (2005)), a journal based in England.

More context: the Liraglutide compound page.